08:52 AM EDT, 10/07/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Tuesday that a phase 3 trial of its experimental drug, tremfya, in adults with moderately to severely active ulcerative colitis showed "clinically meaningful" rates of clinical and endoscopic remission at 48 weeks.

The company said the results build on earlier week 12 data, in which patients receiving tremfya induction followed by maintenance dosing showed continued improvement across all key measures compared with placebo.

Clinically meaningful results were observed across patient subgroups, regardless of prior treatment with biologics or JAK inhibitors, the drugmaker said.